Versatile multigene expression biomarker for predicting clinical platinum sensitivity in non-small cell lung cancer (NSCLC) and ovarian cancer (OC).

e18502 Background: There are no established biomarkers for prediction of clinical platinum sensitivity. A new platinum response prediction method using multigene expression is reported. Methods: We used a Drug Response Predictor (DRP) which is a microarray-based mRNA expression method previously described and validated (Wang et al JNCI 2013;105:1284–1291). The DRP combines in vitro sensitivity with baseline transcriptomics and is secondarily processed through mRNA expression patterns of more than 3.000 tumors in order to evaluate only the expressed genes of clinical relevance. Three datasets available through Gene Expression Omnibus were used: A) 133 NSCLC patients randomized to receive adjuvant chemotherapy containing platinum (n = 71) or no adjuvant treatment (n = 62) (GSE14814) (Zhu et al JCO 2010;28:4417-4424), B) 35 OC patients treated with a platinum (GSE9899) (Tothill et al Clin Cancer Res 2008 Aug 15;14(16):5198-208) and C) 28 OC patients treated with a platinum-containing regimen (GSE23554) (Marc...